NEW DELHI: Drug leading Sun Pharmaceutical Industries on Thursday reported an two-fold leap in consolidated net profit to Rs 894.
15 crore for the quarter ended March 2021, largely due to strong functionality in the Indian industry.
The company had posted a net profit of Rs 399.
84 crore in the corresponding period of the prior financial, Sun Pharma stated in a regulatory filing.
Consolidated total earnings from operations stood at Rs 8,522.
98 crore for the quarter under consideration.
It had been 8,184.
94 crore in exactly the identical period one year before, it included.
For the complete financial 2020-21, the business posted a net profit of Rs 2,903.
82 crore as against Rs 3,764.
93 crore in the last year.
The corporation’s total earnings from operations stood at Rs 33,498.
14 crore for its fiscal year ended March 2021.
It had been Rs 32,837.
50 crore at FY20, it included.
“FY21 has been a year marked with an extremely volatile business environment because of the international Covid-19 outbreak and lockdowns in a variety of nations.
“Despite those challenges, I’m pleased to find that we’ve managed to keep business continuity and document positive general development,” Sun Pharmaceutical Industries MD Dilip Shanghvi stated.
While the corporation’s India industry continues to value the typical industry development, its international specialty earnings have continued to demonstrate a growing trend.
Global sales of medication Ilumya for the entire year also have increased by 51 percent to $143 million, he added.
“The organization has paid debt of approximately $580 million in FY21 when compared with debt at March 31, 2020,” Sun Pharma stated.
Earnings of branded formulations in India for Q4 FY21 have been 2,670.
9 croreup by 12.
9 percent on the fourth quarter this past year, accounting for 31.
7 percent of overall sales.
For the complete year FY21, earnings rose 6.
5 percent to Rs 10,343.
2 crore, it added.
“Earnings from the US were $370 million, with a decrease of 1.
3 percent over Q4 this past year and accounting for around 32 percent of total consolidated earnings.
For complete year FY21, earnings were 1,360 million documenting a de-growth of $ 8.
5 percent over the period this past year,” Sun Pharma stated.
The corporation’s earnings in emerging markets have been in USD 192 million to its fourth quarter, and a rise of 2.
8 percent over Q4 this past year.
Total sales in the emerging markets accounted for approximately 17 percent of total consolidated sales for this quarter.
For the complete year FY21, earnings were $780 million, also apartment on exactly the identical period this past year, it included.
“Formulation earnings in Rest of World (ROW) markets, excluding US and Growing market, were $163 million in Q4FY21up by 5.
5 percent over Q4 this past year and accounted for roughly 14 percent of total consolidated earnings.
“For the complete year FY21, earnings were $650 million, up by 1.
9 percent over a period this past year,” Sun Pharma stated.
For its fourth quarter of financial year 2020-21, outside revenue of API have been 435.
7 croredown 9.
9 percent over Q4 this past year.
For FY21, API earnings were 1,950.
4 croreup by 1.
8 percent.
Consolidated R&D investment to the quarter under consideration had been 557.
1 crore, or 6.
6 percent of earnings when compared with 536 crore (6.
6 percent of earnings ) for Q4 this past year.
For the complete year FY21, R&D cost was 2,149.
9 crore, or 6.
5 percent of earnings, Sun Pharma stated.
The corporation’s board has recommended payment of final dividend of Rs 2 per equity share of Re 1 per cent year for the year ended March 31, 2021, it included.
Stocks of Sun Pharmaceutical Industries closed at Rs 699.
75 a scrip on BSEdown 0.
55 percent from the previous close.